HK1210209A1 - Treatment of diseases of endothelial dysfunction and inflammation - Google Patents

Treatment of diseases of endothelial dysfunction and inflammation

Info

Publication number
HK1210209A1
HK1210209A1 HK15110737.0A HK15110737A HK1210209A1 HK 1210209 A1 HK1210209 A1 HK 1210209A1 HK 15110737 A HK15110737 A HK 15110737A HK 1210209 A1 HK1210209 A1 HK 1210209A1
Authority
HK
Hong Kong
Prior art keywords
inflammation
diseases
treatment
endothelial dysfunction
dysfunction
Prior art date
Application number
HK15110737.0A
Other languages
English (en)
Chinese (zh)
Inventor
Wayne Gregory Kimpton
Simon Reeves Bailey
Silviu Itescu
Peter Ghosh
Original Assignee
Mesoblast Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast Inc filed Critical Mesoblast Inc
Publication of HK1210209A1 publication Critical patent/HK1210209A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
HK15110737.0A 2012-12-12 2015-10-29 Treatment of diseases of endothelial dysfunction and inflammation HK1210209A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736361P 2012-12-12 2012-12-12
PCT/AU2013/001452 WO2014089623A1 (en) 2012-12-12 2013-12-12 Treatment of diseases of endothelial dysfunction and inflammation

Publications (1)

Publication Number Publication Date
HK1210209A1 true HK1210209A1 (en) 2016-04-15

Family

ID=50933585

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110737.0A HK1210209A1 (en) 2012-12-12 2015-10-29 Treatment of diseases of endothelial dysfunction and inflammation

Country Status (12)

Country Link
US (2) US20160175360A1 (ja)
EP (2) EP2931876B1 (ja)
JP (4) JP6572130B2 (ja)
KR (3) KR102506612B1 (ja)
CN (2) CN105358163B (ja)
AU (3) AU2013360024B2 (ja)
CA (1) CA2893942C (ja)
ES (1) ES2742035T3 (ja)
HK (1) HK1210209A1 (ja)
IL (1) IL239308A0 (ja)
SG (2) SG10201705061RA (ja)
WO (1) WO2014089623A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009070842A1 (en) 2007-12-04 2009-06-11 Proteobioactives Pty Ltd Protection of progenitor cells and regulation of their differentiation
WO2022114111A1 (ja) * 2020-11-27 2022-06-02 マルホ株式会社 医薬品又は化粧品用組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
DK1003501T3 (da) 1997-04-02 2005-07-18 Brigham & Womens Hospital Anvendelse af et middel til reduktion af risikoen for kardiovaskulær sygdom
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
DE19939781C2 (de) 1999-08-21 2003-06-18 Schott Glas Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken
EP1807510A4 (en) 2004-09-24 2008-01-23 Angioblast Systems Inc MEMP (MULTIPOTENTIAL EXPANDED MESENCHYMAL PRECURSOR CELL PROGENY) AND USES THEREOF
ES2654428T3 (es) 2005-04-12 2018-02-13 Mesoblast, Inc. Aislamiento de células multipotenciales adultas por fosfatasa alcalina no específica de tejido
US20080241112A1 (en) * 2005-05-10 2008-10-02 Christof Westenfelder Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media
US20080260703A1 (en) * 2007-04-23 2008-10-23 Medistem Labortories Treatment of Insulin Resistance and Diabetes
WO2009070842A1 (en) * 2007-12-04 2009-06-11 Proteobioactives Pty Ltd Protection of progenitor cells and regulation of their differentiation
SG10201510586PA (en) * 2008-06-30 2016-01-28 Mesoblast Inc Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
CN104546912B (zh) * 2008-11-20 2019-11-08 中胚有限公司 用于治疗胰功能异常的方法
WO2010138180A2 (en) * 2009-05-26 2010-12-02 The University Of Vermont And State Agriculture College Compositions and methods for cardiac tissue repair
US20120195969A1 (en) * 2010-09-29 2012-08-02 Aidan Research And Consulting, Llc Treatment of acne by conditioned media
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
CN109276706A (zh) 2011-06-03 2019-01-29 麦瑟布莱斯特公司 治疗或预防神经性疾病的方法
AU2012278925B2 (en) 2011-07-04 2016-05-19 Mesoblast, Inc. Methods of treating or preventing rheumatic disease
IN2015DN00934A (ja) * 2012-08-01 2015-06-12 United Therapeutics Corp
ES2697573T3 (es) * 2013-01-09 2019-01-25 United Therapeutics Corp Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas

Also Published As

Publication number Publication date
EP2931876B1 (en) 2019-05-29
CA2893942C (en) 2023-03-28
JP6829288B2 (ja) 2021-02-10
KR102217962B1 (ko) 2021-02-22
US20160175360A1 (en) 2016-06-23
AU2021250848A1 (en) 2021-11-04
AU2019202960B2 (en) 2021-07-29
AU2013360024B2 (en) 2019-02-28
WO2014089623A1 (en) 2014-06-19
IL239308A0 (en) 2015-07-30
KR20150093732A (ko) 2015-08-18
JP2021073240A (ja) 2021-05-13
SG11201504340YA (en) 2015-07-30
AU2013360024A1 (en) 2015-07-02
JP6572130B2 (ja) 2019-09-04
CA2893942A1 (en) 2014-06-19
JP2023030116A (ja) 2023-03-07
JP2019214571A (ja) 2019-12-19
CN105358163A (zh) 2016-02-24
KR20220029758A (ko) 2022-03-08
US20240115618A1 (en) 2024-04-11
EP2931876A1 (en) 2015-10-21
EP3556850A1 (en) 2019-10-23
KR102367981B1 (ko) 2022-02-25
AU2019202960A1 (en) 2019-05-16
ES2742035T3 (es) 2020-02-12
KR20210021104A (ko) 2021-02-24
JP7201715B2 (ja) 2023-01-10
SG10201705061RA (en) 2017-07-28
CN105358163B (zh) 2020-09-11
EP2931876A4 (en) 2016-05-25
JP2016504311A (ja) 2016-02-12
KR102506612B1 (ko) 2023-03-06
CN111840329A (zh) 2020-10-30

Similar Documents

Publication Publication Date Title
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
HK1211474A1 (en) Treatment of immune-related and inflammatory diseases
HK1198631A1 (en) Prevention and treatment of ocular conditions
EP2670434A4 (en) TREATMENT OF TAUOPATHIA
HK1199015A1 (en) Treatment of inflammation
EP2723347A4 (en) PREVENTING AND TREATING INFLAMMATORY DISEASES
HK1206623A1 (en) Pharmaceutical compositions and treatment of mastitis
HK1220352A1 (zh) 和神經變性疾病的治療
HK1211213A1 (en) Treatment of diseases involving mucin
HK1204573A1 (en) Treatment of inflammatory skin disorders
HK1209639A1 (en) Gpbp-1 inhibition and its therapeutic use gpbp-1
HK1213175A1 (zh) 介導的疾病和/或病症的治療和/或預防
HK1203430A1 (en) Bisarylsulfonamides useful in the treatment of inflammation and cancer
EP2710017A4 (en) MACROCYCLIC THERAPEUTIC AGENTS AND METHODS OF TREATMENT
HK1210209A1 (en) Treatment of diseases of endothelial dysfunction and inflammation
ZA201401800B (en) Novel plant defensins and use in the treatment of proliferative diseases
HK1194977A1 (zh) 奈妥比坦與帕洛諾司瓊的具療效的組合
GB201100651D0 (en) Treatment of inflammation
AU2012900272A0 (en) Treatment and inhibition of corneal erosions
GB201201779D0 (en) Treatment of inflammatory disorders